Accrued Expenses

12 Months Ended

Dec. 31, 2018

8.	ACCRUED EXPENSES

Accrued expenses consisted of the following:

	December 31,
	2018		2017
Accrued clinical operations and trials costs	$	4,914,881	$	2,003,799
Accrued product development costs		2,222,093		1,255,439
Accrued compensation		2,253,621		1,335,672
Accrued other		460,596		146,609
Total	$	9,851,191	$	4,741,519